Armata Pharmaceuticals Inc

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded in 1989 and is headquartered in Los Angeles, CA.

LOS ANGELES , Sept. 5, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D.

Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

LOS ANGELES , Aug. 26, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Mina Pastagia, M.D., MS, Chief Medical Officer, will deliver a poster presentation at the 2024 Military Health System Research Symposium (MHSRS), which is being held August 26-29 in Kissimmee, FL.

Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium

LOS ANGELES, Aug. 15, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced the appointment of life sciences accounting and finance veteran David House as Senior Vice President, Finance, effective August 16 th. Armata's Corporate Controller, Richard Rychlik, will retain the position of Controller.

Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer

LOS ANGELES , Aug. 13, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2024, and provided a corporate update.  Second Quarter 2024 and Recent Developments: Announced completion of enrollment in its Tailwind Phase 2 clinical study of inhaled AP-PA02 in patients with Non-Cystic Fibrosis Bronchiectasis (NCFB) and chronic pulmonary Pseudomonas aeruginosa (P.

Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update

Phase 1b/2a diSArm trial evaluating AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia   LOS ANGELES , July 30, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received an additional $5.25 million of non-dilutive funding pursuant to a previously announced Department of Defense grant, received through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. The grant was awarded to Armata to support clinical development of its optimized phage candidate, AP-SA02, as a potential treatment for complicated Staphylococcus aureus bacteremia.

Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Tailwind is evaluating inhaled AP-PA02 in non-cystic fibrosis bronchiectasis (NCFB), its second patient population, following successful evaluation in patients with cystic fibrosis (SWARM-P.a.) in 2023 Phase 2 Topline data anticipated in 2H 2024 followed by potential initiation of a pivotal bronchiectasis trial in 2025 LOS ANGELES , July 11, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has achieved full enrollment in its Tailwind Phase 2 clinical study of inhaled AP-PA02 in patients with NCFB and chronic pulmonary Pseudomonas aeruginosa (P.

Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

LOS ANGELES , July 10, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will deliver a presentation at Viruses of Microbes 2024, which is being held July 15-19, 2024, in Cairns, Australia.   Details of the presentation are as follows: Title: Advancing Bacteriophage Therapy from Discovery to Clinical Trials Session: Phage Therapy Session 2 – Clinical Application Presenter: Steven Branston, Australia Site Head Day: Thursday, July 18 Time: 11:20am-11:40am AEST (9:20pm-9:40pm EDT on Wednesday, July 17) For more information: https://www.vom2024.org/ About Armata Pharmaceuticals, Inc. Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology.

Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024

LOS ANGELES , May 7, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended March 31, 2024, and provided a corporate update.  First Quarter 2024 and Recent Developments: Entered into a $35.0 million secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Armata's principal shareholder.

Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update

LOS ANGELES , March 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its fourth quarter and full-year ended December 31, 2023, and provided a corporate update.  Fourth Quarter 2023 and Recent Developments: Continued to advance the Phase 2a portion of the Company's diSArm study of AP-SA02 as a potential treatment for Staphylococcus aureus bacteremia with continued ability to dose escalate due to phage purity, as well as its Phase 2 Tailwind study of AP-PA02 in patients with non-cystic fibrosis bronchiectasis (NCFB).

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update

Innoviva

Proceeds to be used to continue to advance rigorously designed clinical trials of Armata's high purity phage-based therapeutic candidates LOS ANGELES , March 4, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder. The gross proceeds to be received by the Company at closing are $35 million before deducting transaction-related expenses.

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

LOS ANGELES , Feb. 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Mina Pastagia, M.D., Chief Medical Officer, will deliver a presentation at the 6th Annual Bacteriophage Therapy Summit, which is being held February 27-29 in Boston.

Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit

LOS ANGELES , Nov. 14, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its third quarter ended September 30, 2023, and provided a corporate update. Third Quarter 2023 and Recent Developments: Reported accelerating enrollment in the Phase 2a portion of the diSArm study of AP-SA02 as a potential treatment for Staphylococcus aureus bacteremia, as well as the Phase 2 Tailwind study of AP-PA02 in non-cystic fibrosis bronchiectasis (NCFB) patients with Pseudomonas aeruginosa lung infections.

Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update

LOS ANGELES , Oct. 30, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that topline data from the Company's Phase 1b/2a SWARM-P.a. clinical trial evaluating AP-PA02, a novel, inhaled multi-phage therapeutic for the treatment of chronic pulmonary Pseudomonas aeruginosa infections in people with cystic fibrosis (CF) will be mentioned during the North American Cystic Fibrosis Conference (NACFC) Plenary II session.

Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

LOS ANGELES , Oct. 19, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical stage biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that its Chief Medical Officer, Mina Pastagia, M.D., MS, will deliver a presentation at Phage Futures: Global Digital Summit 2023, which is being held virtually on October 25 th.

Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023

Initiation of the Phase 2a portion follows DRC review of positive safety and tolerability data from recently completed Phase 1b portion Study being conducted in partnership with the U.S. Department of Defense LOS ANGELES , Sept. 26, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the first patient has been dosed in the Phase 2a portion of the Company's diSArm study of AP-SA02 as a potential treatment for Staphylococcus aureus bacteremia.

Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

MARINA DEL REY, Calif., Sept. 21, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D.

Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

Armata Pharma (ARMP) stock skyrockets 130% in a month due to encouraging progress of the company's pathogen-targeting natural and synthetic phage candidates.

Armata Pharma (ARMP) Stock Surges 130% in a Month: Here's Why

Armata Pharmaceuticals, Inc. (ARMP) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ARMP's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

Armata Pharmaceuticals, Inc. (ARMP) Now Trades Above Golden Cross: Time to Buy?

LOS ANGELES , Aug. 14, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2023, and provided a corporate update.   Second Quarter 2023 and Recent Developments: Announced leadership transition whereby world‐renowned healthcare leader and former Innoviva Board member Dr. Deborah L.

Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

MARINA DEL REY, Calif. , May 31, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced an oral presentation on the company's recently completed Phase 1b/2a SWARM-P.a.

Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy

Armata Pharmaceuticals, Inc. (ARMP) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.30 per share a year ago.

Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates

MARINA DEL REY, Calif. , May 11, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended March 31, 2023, and provided a corporate update.

Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update

MARINA DEL REY, Calif., March 16, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its fourth quarter and full-year 2022, and provided a corporate update.

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update

AP-PA02 is well-tolerated and data supports progression to Phase 2b Also announces first subject dosed in Phase 2 'Tailwind' clinical trial of inhaled AP-PA02 in patients with Non-Cystic Fibrosis Bronchiectasis (NCFB) NCFB represents Armata's third active clinical program MARINA DEL REY, Calif. , March 6, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced positive topline results from the completed Phase 1b/2a SWARM-P.a.

Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis

MARINA DEL REY, Calif. , Jan. 10, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has closed a secured convertible credit agreement (the "credit agreement") with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder.

News for Armata Pharmaceuticals Inc Stock (ARMP)